Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

认知增强作为可卡因药物治疗的目标

基本信息

批准号：
8105851
负责人：
Mehmet Sofuoglu
金额：
$ 35.75万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-04-01 至 2015-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8105851
关键词：
Alzheimer&apos s Disease Attention Behavior Behavior Therapy Cholinesterase Inhibitors Chronic Clinical Clinical Trials Cocaine Cocaine Dependence Cocaine Users Cognitive Cognitive deficits Controlled Clinical Trials Counseling Crime Decision Making Development Digit structure Dose Double-Blind Method Effectiveness Galantamine Goals HIV HIV Infections Hepatitis Impaired cognition Individual Intravenous Lead Literature Marketing Measures Mediating Memory Methadone Nootropic Agents Outcome Measure Participant Patient Self-Report Patients Performance Pharmaceutical Preparations Pharmacotherapy Pilot Projects Placebo Control Placebos Preparation Prize Public Health Randomized Randomized Clinical Trials Reaction Time Relative (related person)Reporting Risk Series Short-Term Memory Signal Transduction Specimen Testing Time Treatment outcome Urine Violence addiction base cocaine use cognitive enhancement cognitive function contingency management effective therapy follow-up improved information processing novel response visual information

项目摘要

DESCRIPTION (provided by applicant): Cocaine addiction continues to be an important public health problem, with over 2.1 million regular cocaine users in the US. The risks associated with this addiction are enormous and include increased crime and violence as well as increased risk of HIV, and hepatitis. The presence of intravenous cocaine use is one of the strongest predictors for HIV infection, increasing the risk by about four times. Given that there are no effective medication treatments for cocaine addiction, new treatment approaches that will lead to effective treatments are needed. Chronic cocaine use is associated with significant cognitive impairment, which interferes with effective behavioral treatment of this addiction. This proposal will target cognitive function to develop effective treatments for cocaine addiction. We propose to evaluate the effectiveness of a cognitive enhancer, galantamine, for the treatment of cocaine addiction. Galantamine is a cholinesterase inhibitor that is approved for the treatment of Alzheimer's disease. In our pilot studies, galantamine improved attention function in cocaine users and reduced cocaine use. We are proposing a 12-week, double-blind, placebo-controlled, randomized clinical trial. One hundred and twenty cocaine addicted individuals will be randomly assigned one of three treatment groups: placebo, 8 mg/day, or 16 mg/day for galantamine treatment. The main outcome measure will be cocaine use and cognitive performance measures, including measures of attention. We hypothesize that galantamine will be more effective than placebo in reducing cocaine use and improving measures of attention. We also hypothesize that improvement in cocaine use will be mediated by improvement in attention function. This proposal may lead to development of effective treatments for cocaine addiction. PUBLIC HEALTH RELEVANCE: Cocaine addiction continues to be an important public health problem and there are no effective medication treatments for this addiction. This proposed application will test a promising medication, galantamine, for the treatment of cocaine addiction.

描述（由申请人提供）：可卡因成瘾仍然是一个重要的公共卫生问题，美国有超过210万普通的可卡因使用者。与这种成瘾相关的风险是巨大的，包括增加犯罪和暴力以及艾滋病毒和肝炎的风险增加。静脉可卡因使用的存在是HIV感染的最强预测因子之一，将风险增加了大约四倍。鉴于没有有效的可卡因成瘾药物治疗方法，因此需要新的治疗方法，这些方法将导致有效治疗。慢性可卡因的使用与严重的认知障碍有关，这会干扰这种成瘾的有效行为治疗。该建议将针对认知功能，以开发可卡因成瘾的有效治疗方法。我们建议评估认知增强子Gagalanmine对可卡因成瘾的有效性。甘氨酸是一种胆碱酯酶抑制剂，被批准用于治疗阿尔茨海默氏病。在我们的试点研究中，甘坦明明改善了可卡因使用者的注意力功能，并减少了可卡因的使用。我们提议进行为期12周的双盲，安慰剂对照，随机临床试验。一百二十个可卡因上瘾的个体将被随机分配三个治疗组之一：安慰剂，8 mg/天或16 mg/day用于甘氨酸治疗。主要结果指标将是可卡因的使用和认知绩效指标，包括关注度量。我们假设甘兰胺在减少可卡因的使用和改善注意力措施方面将比安慰剂更有效。我们还假设可卡因使用的改善将由注意力功能的提高介导。该提案可能导致开发可卡因成瘾的有效治疗方法。公共卫生相关性：可卡因成瘾仍然是一个重要的公共卫生问题，这种成瘾没有有效的药物治疗。该提出的应用将测试一种有希望的药物甘坦明，以治疗可卡因成瘾。